跳至主要内容
临床试验/CTRI/2023/08/056330
CTRI/2023/08/056330已完成3 期

A Prospective, Randomised, Placebo Controlled Study to Evaluate the Impact ofGLUBLOC™ on postprandial blood glucose and insulin levels in healthy individuals post highcarbohydrate meal intake. - NI

My Pura Vida Wellness Pvt Ltd0 个研究点目标入组 35 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
35

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Aged between 18–60 years,
  • BMI between 20 and 29.9 kg/m2
  • Fasting blood glucose = 5.7 mmol/l (or) = 99 mg/dl

排除标准

  • History of hypersensitivity to any of the investigational product, excipients, or Any known food allergies.
  • Pre-existing medical condition or taking medication known to affect glucose regulation and/or influence digestion and absorption of nutrients
  • History of diabetes mellitus (type I/II) or they used antihyperglycemic drugs or insulin to treat diabetes or related conditions
  • Use steroids, protease inhibitors or antipsychotic medicines as these drugs are known to impact glucose metabolism and body fat distribution.
  • Subjects with the history of uncontrolled hypertension and/or hyperthyroidism.
  • History of alcoholism
  • Subjects with psychiatric or neurological disability or mental health disorder
  • Subjects with serious health conditions such as cardiac disease, renal dysfunction, and cancers.
  • Female subjects who are pregnant or had planned for pregnancy in the following months or were breast-feeding.
  • Subjects who refuse to sign informed consent.
  • According to the investigator’s opinion, participants who are deemed unable to comply with the test requirements or otherwise deemed unsuitable.

研究者

发起方
My Pura Vida Wellness Pvt Ltd

相似试验

Impact of GLUBLOC™ on postprandial blood glucose and... | 临床试验